Compare IMMR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | ABOS |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.5M | 182.0M |
| IPO Year | 1999 | 2021 |
| Metric | IMMR | ABOS |
|---|---|---|
| Price | $6.28 | $2.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $13.50 | $8.00 |
| AVG Volume (30 Days) | ★ 461.6K | 292.3K |
| Earning Date | 04-13-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $35,013,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $303.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $0.99 |
| 52 Week High | $8.15 | $3.60 |
| Indicator | IMMR | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 51.64 |
| Support Level | $5.78 | $2.24 |
| Resistance Level | $6.39 | $2.77 |
| Average True Range (ATR) | 0.24 | 0.14 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 44.01 | 66.41 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.